​

Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?

OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary

Protagonist Therapeutics is owned by 41.10% institutional investors, 1.22% insiders, and 57.67% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.24% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.57% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics41.10%1.22%57.67%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.72M15.24%$848.60M
Farallon capital management6.20M9.76%$411.60M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.76M9.06%$382.39M
Vanguard group5.41M8.49%$472.83M
State street3.17M4.98%$210.30M
Ubs group2.77M4.34%$241.93M
Bvf inc/il2.56M4.03%$170.12M
Johnson & johnson2.45M3.84%$213.91M
Wellington management group llp1.91M3.00%$126.78M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M38.57%$213.91M
Lynx1 capital management lp700.01K9.47%$46.50M
Aquilo capital management81.69K7.08%$3.95M
Bvf inc/il2.56M6.90%$170.12M
Adar1 capital management989.18K6.17%$65.71M
Rtw investments, lp5.76M4.71%$382.39M
Nationale-nederlanden powszechne towarzystwo emerytalne571.83K4.43%$49.94M
Commodore capital lp1.02M3.32%$68.09M
Knott david m jr73.00K2.95%$6.38M
Birchview capital, lp48.00K2.41%$3.19M

Top Buyers

HolderShares% AssetsChange
Vanguard group5.41M0.01%1.16M
Marshall wace, llp1.09M0.07%1.09M
Ubs group2.77M0.04%874.01K
Wellington management group llp1.91M0.02%870.71K
Nationale-nederlanden powszechne towarzystwo emerytalne571.83K4.43%571.83K

Top Sellers

HolderShares% AssetsChange
Pacer advisors---1.88M
Deep track capital, lp---1.72M
Fairmount funds management---931.89K
Jefferies financial group5.00K0.00%-816.50K
Bvf inc/il2.56M6.90%-650.13K

New Positions

HolderShares% AssetsChangeValue
Marshall wace, llp1.09M0.07%1.09M$72.11M
Nationale-nederlanden powszechne towarzystwo emerytalne571.83K4.43%571.83K$49.94M
Clearbridge investments489.84K0.03%489.84K$42.78M
Eagle asset management357.63K0.07%357.63K$12.59M
Jennison associates331.16K0.02%331.16K$28.92M

Sold Out

HolderChange
Tfc financial management-1.00
Ifp advisors-5.00
Mendota financial group-6.00
Federated hermes-7.00
Nelson, van denburg & campbell wealth management group-11.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025156-44.68%26,213,291-62.92%410.33%90-30.23%45-58.33%
Sep 30, 2025140-48.91%21,573,409-68.80%330.29%55-67.26%60-20.00%
Jun 30, 2025279-3.79%70,876,6488.54%1111.04%1673.73%78-13.33%
Mar 31, 202519-92.31%15,761,655-75.08%250.24%12-91.18%5-93.33%
Dec 31, 2024147-40.49%31,832,545-48.43%510.52%84-45.81%42-35.38%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.56M5.57%3.56M
Vanguard Total Stock Mkt Idx Inv1.97M3.08%5.26K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
iShares Russell 2000 ETF1.40M2.20%389.38K
State Street® SPDR® S&P® Biotech ETF1.10M1.72%-5.88K
Vanguard Health Care Inv1.06M1.67%1.06M
SPDR® S&P Biotech ETF983.05K1.58%2.19K
T. Rowe Price Health Sciences955.19K1.50%-74.97K
UBS: US Equity Small Cap Growth744.87K1.25%-

Recent Insider Transactions

DateNameRoleActivityValue
Feb 17, 2026Williams Lewis T-Sell$1.48M
Feb 06, 2026Waddill William D.-Sell$1.67M
Jan 27, 2026PATEL DINESH V PH D President and CEOSell$338.42K
Jan 23, 2026PATEL DINESH V PH D President and CEOSell$1.63M
Jan 26, 2026PATEL DINESH V PH D President and CEOSell$897.54K

Insider Transactions Trends

DateBuySell
2026 Q1-14
2025 Q4-3
2025 Q3-6
2025 Q2-3
2025 Q1-8

PTGX Ownership FAQ

Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 41.10%, followed by 1.22% insiders and 57.68% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 381.47%, which Protagonist Therapeutics falls below.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.72M shares, 15.24%), Farallon capital management (6.2M shares, 9.76%), and Blackrock (5.76M shares, 9.39%). Together, they hold 34.38% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 38.57% of its assets in 2.45M Protagonist Therapeutics shares, valued at 213.91M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 5.57% of its total shares outstanding invested in 3.56M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools